Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Successful rapid desensitization with 5-fluorouracil in a patient with metastatic sigmoid colon cancer: A case report.

Created on 13 Aug 2026

Authors

Aysu Okumuş Güçlü, Orbay Tutku Seren, Barış Gezici, Papatya Bayrak Değirmenci

Published in

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. Pages 10781552261478571. Aug 12, 2026. Epub Aug 12, 2026.

Abstract

Introduction5-Fluorouracil (5-FU) is an antimetabolite widely used in colorectal, gastric, breast, and other solid tumors. Hypersensitivity reactions are uncommon but may be severe.Case ReportWe report a 63-year-old woman with metastatic sigmoid colon cancer who developed an anaphylactic reaction during the second course of a 5-FU-containing regimen, specifically following the bolus infusion. Skin prick and intradermal tests performed four weeks later were negative.Management & OutcomeAs no equally efficacious alternative existed within the planned regimen, rapid intravenous desensitization was performed using a 16-step protocol with four dilution solutions. Desensitization was completed without adverse events, and the subsequent 48-h continuous 5-FU infusion was also well tolerated.DiscussionThis case adds to the limited literature on 5-FU desensitization and underscores its feasibility and safety in agent-dependent patients.

PMID:
42585552
Bibliographic data and abstract were imported from PubMed on 13 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement